KAIROS PHARMA LTD (KAPA) Stock News

USA - NYSEARCA:KAPA - US48301N1046 - Common Stock

0.8755 USD

-0.05 (-5.66%)

Last: 11/11/2025, 8:20:32 PM

0.8705 USD

0 (-0.57%)

After Hours: 11/11/2025, 8:20:32 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

KAPA Latest News, Press Relases and Analysis

All

Press Releases

8 hours ago - By: Benzinga - Mentions: AIM STXS PRPH LUCY ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

8 days ago - By: Kairos Pharma Ltd

Kairos Pharma Provides Shareholder Update

23 days ago - By: Kairos Pharma, Ltd

Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

a month ago - By: Kairos Pharma, Ltd

Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025

4 months ago - By: Benzinga - Mentions: SLP WFC RANI RVYL ...

Nasdaq Gains Over 100 Points; Wells Fargo Earnings Top Views

2 months ago - By: Kairos Pharma, Ltd

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

2 months ago - By: Kairos Pharma, Ltd

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer

2 months ago - By: Kairos Pharma, Ltd

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

2 months ago - By: Kairos Pharma, Ltd

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

4 months ago - By: Kairos Pharma, Ltd

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

4 months ago - By: Kairos Pharma, Ltd

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer